7.96
-0.02
(-0.25%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 7.89 - 8.49 |
| 52 week | 3.86 - 9.92 |
| Open | 8.41 |
| Vol / Avg. | 4.01M/1.31M |
| Mkt cap | 900.76M |
| P/E | - |
| Div/yield | - |
| EPS | -0.51 |
| Shares | 113.16M |
| Beta | 1.51 |
| Inst. own | 64% |
Events
Aug 5, 2013
Q2 2013 Halozyme Therapeutics, Inc. Earnings Release
May 16, 2013
Halozyme Therapeutics, Inc. Annual Shareholder Meeting
May 14, 2013
Halozyme Therapeutics, Inc. at Bank of America Merrill Lynch Health Care Conference
May 8, 2013
Q1 2013 Halozyme Therapeutics, Inc. Earnings Conference Call
May 7, 2013
Q1 2013 Halozyme Therapeutics, Inc. Earnings Release
Mar 12, 2013
Halozyme Therapeutics, Inc. at Barclays Healthcare Conference
Feb 25, 2013
Q4 2012 Halozyme Therapeutics, Inc. Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -163.00% | -126.53% |
| Operating margin | -156.30% | -126.70% |
| EBITD margin | - | -124.15% |
| Return on average assets | -61.50% | -53.42% |
| Return on average equity | -192.13% | -179.24% |
| Employees | 152 | - |
| Carbon Disclosure Rating | - | - |
Address
11388 Sorrento Valley Road
SAN DIEGO, CA 92121
United States - Map
+1-858-7948889 (Phone)
+1-858-7048311 (Fax)
SAN DIEGO, CA 92121
United States - Map
+1-858-7948889 (Phone)
+1-858-7048311 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical company. The Company�s research focuses primarily on human enzymes that alter the extracellular matrix. The Company�s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter), ViroPharma Incorporated (ViroPharma) and Intrexon Corporation (Intrexon), with three product candidates.
Officers and directors
| Kenneth J. Kelley Ph.D. | Independent Chairman of the Board | |
| Gregory I. Frost Ph.D. | President, Chief Executive Officer, Director | |
| Kurt A. Gustafson | Chief Financial Officer, Vice President | |
| H. Michael Shepard Ph.D. | Vice President, Chief Scientific Officer | |
| Jean I. Liu J.D. | Vice President, General Counsel, Secretary | |
| James P. Shaffer | Vice President, Chief Commercial Officer | |
| Matthew L. Posard | Director | |
| Robert L. Engler M.D. | Independent Director | |
| Kathryn E. Falberg | Independent Director | |
| Randal J. Kirk | Independent Director |